×
About 621,608 results

Improving Shingles Vaccination Rates in Family Medicine.
https://doi.org/10.12788/jfp.0218
The Journal of Family Practice; Luther JS

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practices. • Implement strategies to increase patient acceptance of herpes zoster and other vaccinations. • Use available resources to increase awareness amo...

ESMO Virtual Congress 2020: Abstracts
https://www.esmo.org/meetings/esmo-virtual-congress-2020/abstracts

Sep 19th, 2020 - Abstract submission categories Basic science Biliary tract cancer, incl. cholangiocarcinoma Biomarkers (agnostic) Breast cancer, early stage Breast cancer, locally advanced Breast cancer, metastatic CNS tumours Colorectal cancer Developmental therapeutics Endocrine tumours Genitourinary tumours, prostate Genitourinary tumours, non-prostate Gynaecological cancers Haematological mal...

ESMO Guideline for Cancer Patient Management During the COVID-19 Pandemic
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic?hit=ehp

Sep 18th, 2020 - These recommendations should be used as guidance for prioritising the various aspects of cancer care in order to mitigate the negative effects of the COVID-19 pandemic on the management of cancer patients. The situation is evolving, and pragmatic actions may be required to deal with the challenges of treating patients, while ensuring their rights, safety and wellbeing.

Orvacabtagene Autoleucel Confers High Objective Responses in Patients With Relapsed/Refractory Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200209/full/

May 30th, 2020 - Various dose levels of orvacabtagene autoleucel (orva-cel), an anti–B-cell maturation antigen (BCMA) CAR T-cell therapy, was associated with manageable safety and high objective responses in patients with relapsed/refractory multiple myeloma (MM) who had been heavily pretreated.

CC-92480 Shows Encouraging Efficacy in First-in-Human Study for R/R Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/cc92480-shows-encouraging-efficacy-in-firstinhuman-study-for-rr-multiple-myeloma

May 30th, 2020 - An ongoing study of CC-92480 in combination with dexamethasone demonstrated favorable activity and safety data in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM), according to a presentation from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

First-in-Human Study Shows Favorable Activity With CC-92480 in Relapsed/Refractory Myeloma
https://www.targetedonc.com/view/first-in-human-study-shows-favorable-activity-with-cc-92480-in-relapsed-refractory-myeloma

May 30th, 2020 - Favorable activity and safety findings were demonstrated with the combination of CC-92480 plus dexamethasone as treatment of patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in an ongoing study, according to a presentation from the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.

AMG 510 Shows Clinical Activity in Advanced KRAS G12C-Mutant Solid Tumors
https://www.onclive.com/conference-coverage/asco-2020/amg-510-shows-clinical-activity-in-advanced-kras-g12c-mutant-solid-tumors

May 30th, 2020 - AMG 510, a novel KRAS G12C inhibitor, demonstrated early evidence of a consistent safety profile and anticancer activity across a range of advanced KRAS G12C-mutant solid tumors other than non–small cell lung cancer (NSCLC) and colorectal cancer (CRC), according to results presented at the 2020 ASCO Virtual Scientific Program.

Interim ZUMA-5 Analysis Shows Promise for Axi-Cel in Relapsed/Refractory iNHL
https://www.onclive.com/conference-coverage/asco-2020/interim-analysis-from-phase-ii-zuma5-study-shows-promise-for-axicel-in-rr-inhl

May 30th, 2020 - An interim analysis of the phase II ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel; Yescarta) demonstrated significant and durable clinical benefit, with high rates of overall response rate (ORR) and complete response (CR) observed, as well as a manageable safety profile in patients with relapsed or refractory indolent non-Hodgkin lymphoma.

Off-the-Shelf CAR-T Cell Therapy ALLO-501 Induces High Responses in Relapsed/Refractory B-Cell Lymphomas
https://www.onclive.com/conference-coverage/asco-2020/off-the-shelf-cart-cell-therapy-allo501-induces-high-responses-in-relapsed-refractory-bcell-lymphomas

May 30th, 2020 - The allogeneic chimeric antigen receptor (CAR)-T cell therapy ALLO-501, paired with the monoclonal antibody ALLO-647, has clinical activity and a manageable safety profile in patients with relapsed/refractory large B-cell or follicular lymphoma. The first-in-human findings were presented during the virtual scientific program of the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting.

AMG 510 Demonstrates Early Promise in Advanced KRAS G12C-Mutant Solid Tumors
https://www.targetedonc.com/view/amg-510-demonstrates-early-promise-in-advanced-kras-g12c-mutant-solid-tumors

May 30th, 2020 - Early signals of anti-tumor activity and safety were demonstrated with the novel KRAS G12C inhibitor, AMG 510, in multiple advanced solid tumors that harbor KRAS G12C mutations, according to results presented at the 2020 ASCO Virtual Scientific Program.

CAR T-Cell Therapy With Axi-Cel Holds Promise in R/R Indolent NHL
https://www.targetedonc.com/view/car-t-cell-therapy-with-axi-cel-holds-promise-in-r-r-indolent-nhl

May 30th, 2020 - Patients with relapsed or refractory indolent non-Hodgkin lymphoma who were treated with the chimeric antigen receptor (CAR) T-cell therapy of axicabtagene ciloleucel (axi-cel; Yescarta) had high rates of complete response (CR) and demonstrated the agent's manageable safety profile, according to an interim analysis of the phase 2 ZUMA-5 study (NCT03105336) presented as part of the 2020 American...

Mirvetuximab Soravtansine Shows Promise in Platinum-Agnostic Ovarian Cancer
https://www.targetedonc.com/view/mirvetuximab-soravtansine-shows-promise-in-platinum-agnostic-ovarian-cancer

May 30th, 2020 - Encouraging responses and favorable safety was demonstrated with the combination of mirvetuximab soravtansine, plus bevacizumab (Avastin) as treatment of patients with platinum-agnostic ovarian cancer regardless of platinum status, Lucy Gilbert MD, MSc reported in a presentation during the 2020 ASCO Scientific Program.

Apalutamide, Darolutamide, Enzalutamide Yield OS Benefit in nmCRPC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200161/full/

May 29th, 2020 - Final survival results from three randomized, placebo-controlled trials, along with a safety analysis across all three, are helping to clarify the treatment landscape for nonmetastatic castration-resistant prostate cancer (nmCRPC). The results will be presented during the ASCO20 Virtual Scientific Program.

T-DM1 Does Not Improve Safety or Efficacy in HER2-Positive Early Breast Cancer; Favorable iDFS Reported
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200162/full/

May 29th, 2020 - Findings from the primary analysis of the KAITLIN trial suggest that replacement of adjuvant taxane with trastuzumab emtansine (T-DM1) does not improve survival or safety for patients with HER2-positive early-stage breast cancer (Abstract 500). However, both treatments demonstrated outstanding long-term invasive disease–free survival (iDFS) in a high-risk population. Study author Nadia Harbeck,...

Donafenib Improves OS in Hepatocellular Carcinoma Compared With Sorafenib
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200179/full/

May 29th, 2020 - Donafenib significantly improved overall survival (OS) rates compared with sorafenib in patients with hepatocellular carcinoma (HCC) and did so with favorable safety and tolerability, according to a new study (Abstract 4506).

Maintenance PARP-Inhibitor Therapy May Hold Clinically Meaningful Benefits for Women With Recurrent Ovarian Cancer
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200191/full/

May 29th, 2020 - The SOLO2 trial found olaparib maintenance therapy may have clinically relevant effects on overall survival (OS) in women with platinum-sensitive relapsed ovarian cancer (PSROC) with BRCA1/2 mutations (Abstract 6002). Andrés Poveda, MD, of Initia Oncology, Hospital Quirónsalud and GEICO, Spain, presented survival and safety outcomes from the trial during the ASCO20 Virtual Scientific Program.

Savolitinib Shows Promising Efficacy Data in Papillary Renal Cell Carcinoma
https://www.onclive.com/conference-coverage/asco-2020/met-tki-shows-promise-in-papillary-renal-cell-carcinoma

May 29th, 2020 - Savolitinib showed encouraging efficacy data and an improved safety profile compared with sunitinib (Sutent) as a treatment for patients with MET-driven papillary renal cell carcinoma (RCC), according to results that were presented during the 2020 ASCO Virtual Scientific Program.

Promising Responses Seen With Belantamab Mafodotin Triplet for R/R Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/promising-responses-seen-with-belantamab-mafodotin-triplet-for-rr-multiple-myeloma

May 29th, 2020 - Belantamab mafodotin in combination with bortezomib (Velcade) and dexamethasone (B-Vd) demonstrated a high rate of clinical benefit and an acceptable safety profile in patients with relapsed or refractory multiple myeloma, according to preliminary findings from a cohort of the phase 1/2 DREAMM-6 trial.

Updated CARTITUDE-1 Results Continue to Demonstrate Safety, Durable Responses for JNJ-4528 in R/R Multiple Myeloma
https://www.onclive.com/conference-coverage/asco-2020/updated-cartitude1-results-continue-to-demonstrate-safety-durable-responses-for-jnj4528-in-rr-multiple-myeloma

May 29th, 2020 - The chimeric antigen receptor (CAR) T-cell therapy, JNJ-4528, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial. Lead author Jesus G. Berdeja, MD, reported that the overall response rate (ORR) was 100%, with a stringent complete response (...

Zanubrutinib Shows Efficacy, Tolerability in Waldenstrom Macroglobulinemia
https://www.onclive.com/conference-coverage/asco-2020/zanubrutinib-shows-efficacy-tolerability-in-waldenstrom-macroglobulinemia

May 29th, 2020 - Zanubrutinib (Brukinsa) was associated with a higher complete response or very good partial response (CR+VGPR) rate, as well as clinically meaningful advantages in safety and tolerability, compared with ibrutinib (Imbruvica) in patients with Waldenström macroglobulinemia (WM), according to results of the phase 3 ASPEN trial (NCT03053440).